article thumbnail

Outsourcing Peptide Synthesis: Preferred Choice of Drug Developers

Roots Analysis

Owing to the challenges involved in the synthesis process and demands of modern drug development, majority of drug developers in this domain prefer to outsource their development and manufacturing operations to peptide therapeutics contract API manufacturers as a strategic solution to streamline their research and peptide synthesis efforts.

article thumbnail

BioSpace Movers & Shakers, Jan. 1

The Pharma Data

Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector. Prior to joining Taysha, Gara served as vice president of Pharmaceutical Engineering at Sarepta, where he led and managed manufacturing operations for all gene therapy products.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Retail Sales of Plant-Based Foods Surged to $7 Billion in 2020

XTalks

Kyle Gaan, a research analyst at GFI said in the same press release, “2020 was a breakout year for plant-based foods across the store. The growth can also be attributed to the placement of plant-based meat in the meat section, with refrigerated plant-based meat sales growing twice as fast as their frozen counterparts.

Sales 98
article thumbnail

Sanofi offers refunds for Cablivi in novel model for rebates

Pharmaceutical Technology

Designing risk sharing agreements Overall however, this warranty program is similar to previous performance-based risk sharing agreements, says Alex Watt, principal research analyst on GlobalData’s Price Intelligence team. GlobalData is the parent company of Pharmaceutical Technology.

article thumbnail

COVID-19 Vaccine Data Not Expected Until November as FDA Releases Guidelines for Emergency Use Authorizations

XTalks

Related: AMRI Signs Supply Agreement with AstraZeneca to Manufacture COVID-19 Vaccine. Apart from the two months of data required for an EUA review, the FDA has also asked makers to provide detailed information on manufacturing, as well as proposed labels and patient brochures as part of the review. Just another political hit job!

article thumbnail

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. These can include compulsory discounts, manufacturing discounts and more.

Marketing 257